Novartis India Ltd (NOVARTIND) — shareholding pattern, promoter holding, financials and share price
About Novartis India Ltd (NOVARTIND)
Novartis India Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as NOVARTIND and on the BSE under scrip code 500672. Its ISIN is INE234A01025.
Novartis India Ltd is primarily engaged in the Business of Wholesale of pharmaceuticals and medical goods. [1] It imports various medicines to India from different sources across the globe. [2]
Novartis India Limited (NIL) is a subsidiary of the Swiss pharmaceutical company Novartis. It primarily operates in manufacturing and marketing drugs across pharmaceuticals, generics, over-the-counter, and animal health products.
Novartis' history is marked by major mergers, starting with the merge of Ciba and Geigy in 1970, leading to the formation of Novartis in 1996 after Sandoz joined. This historical consolidation forms the backbone of their capabilities today.
Listed peers in Pharmaceuticals: Gujarat Themis Biosyn Ltd, Gufic BioSciences Ltd, SMS Pharmaceuticals Ltd, Aarti Drugs Ltd, Morepen Laboratories Ltd, Panacea Biotec Ltd.
Valuation & Returns
10 Jul 2026At ₹1,500 a share on 10 Jul 2026, Novartis India Ltd (NOVARTIND) was valued at a price-to-earnings ratio of 39.75x against an industry P/E of 36.41x and a price-to-book of 4.72x on a book value of ₹317.92 per share as of Mar 2025. Solomo computes return on equity of 11.87% and return on capital employed of 16.57% from filed results. Earnings ratios use standalone results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 39.75x
- Industry P/E
- 36.41x
- P/B
- 4.72x
- EPS (TTM)
- ₹37.74
- Book value / share
- ₹317.92
- ROE
- 11.87%
- ROCE
- 16.57%
- ROA
- 9.83%
- Debt / equity
- 0.01x
- Dividend yield
- 1.67%
- EBITDA margin
- 37.5%
- 52-week range
- ₹750 – ₹1,588.4
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Novartis India Ltd (NOVARTIND) reported revenue of ₹354 crore, net profit of ₹93 crore and earnings per share of ₹37.74. That compares with revenue of ₹356 crore and net profit of ₹101 crore in Mar 2025. Figures are standalone, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹91 crore and net profit ₹25 crore (standalone).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 400 | 379 | 335 | 356 | 354 |
| Net profit (₹ cr) | -4 | 103 | 85 | 101 | 93 |
| EPS (₹) | -1.51 | 41.86 | 34.5 | 40.87 | 37.74 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | -7.08% | -4.06% | -3.78% | 6.34% |
| Profit growth | 3.74% | 58.52% | - | 18.44% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 70.68% of Novartis India Ltd (NOVARTIND) (unchanged from the previous quarter), foreign institutional investors (FII) hold 0.16% and domestic institutional investors (DII) hold 1.36%. Market capitalisation was ₹3,704 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: Atul Limited 1.52%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 70.68% | - | 0.16% | 1.36% | 29.32% |
| Mar 2026 | 70.68% | - | 0.17% | 0.53% | 29.32% |
| Dec 2025 | 70.68% | - | 0.19% | 0.64% | 29.32% |
| Sep 2025 | 70.68% | - | 0.19% | 0.53% | 29.32% |
| Jun 2025 | 70.68% | - | 0.19% | 0.53% | 29.32% |
| Mar 2025 | 70.68% | - | 0.19% | 0.53% | 29.32% |
| Dec 2024 | 70.68% | - | 0.19% | 0.53% | 29.32% |
| Sep 2024 | 70.68% | - | 0.19% | 0.53% | 29.32% |